GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (OCSE:ORPHA) » Definitions » 3-Year EBITDA Growth Rate

Orphazyme AS (OCSE:ORPHA) 3-Year EBITDA Growth Rate : 0.00% (As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Orphazyme AS 3-Year EBITDA Growth Rate?

Orphazyme AS's EBITDA per Share for the six months ended in Jun. 2022 was kr-778.26.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of Orphazyme AS's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Orphazyme AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orphazyme AS's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's 3-Year EBITDA Growth Rate falls into.



Orphazyme AS 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Orphazyme AS  (OCSE:ORPHA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Orphazyme AS 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (OCSE:ORPHA) Business Description

Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (OCSE:ORPHA) Headlines

No Headlines